Novartis

Narasimhan emphasised that India remains pivotal for talent sourcing and research, despite a shift away from manufacturing

Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company, the drug firm said in a statement. Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India. Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated. There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, i

JB Chemicals & Pharmaceuticals Ltd (JB Pharma)on Tuesday said it has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore. The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing. The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added. On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks ..

Acquisition of the drug, Xiidra, will mark the first big deal by CEO Brent Saunders since he returned to the company in March

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.

Opens floodgates for more generic launches; 40 new brands expected

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%

Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Here are the top headlines of the day

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

Core net income rises to $3.55 billion from $2.8 billion in 2019, against the average analyst forecast in a Refinitiv poll of $3.17 billion

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.